|Heart disease and stroke statistics—2012 update: a report from the American Heart Association|
Writing Group Members, VL Roger, AS Go, DM Lloyd-Jones, EJ Benjamin, ...
Circulation 125 (1), e2-e220, 2012
|Heart disease and stroke statistics—2015 update: a report from the American Heart Association|
D Mozaffarian, EJ Benjamin, AS Go, DK Arnett, MJ Blaha, M Cushman, ...
circulation 131 (4), e29-e322, 2015
|Dabigatran versus warfarin in patients with atrial fibrillation|
SJ Connolly, MD Ezekowitz, S Yusuf, J Eikelboom, J Oldgren, A Parekh, ...
New England Journal of Medicine 361 (12), 1139-1151, 2009
|Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation|
Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
New England Journal of Medicine 345 (7), 494-502, 2001
|Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines|
J Ansell, J Hirsh, E Hylek, A Jacobson, M Crowther, G Palareti
Chest 133 (6), 160S-198S, 2008
|Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety|
J Hirsh, TE Warkentin, SG Shaughnessy, SS Anand, JL Halperin, ...
Chest 119 (1), 64S-94S, 2001
|Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin|
TE Warkentin, MN Levine, J Hirsh, P Horsewood, RS Roberts, M Gent, ...
New England Journal of Medicine 332 (20), 1330-1336, 1995
|Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range|
J Hirsh, JE Dalen, DR Anderson, L Poller, H Bussey, J Ansell, D Deykin
Chest 119 (1), 8S-21S, 2001
|Prevention of venous thromboembolism|
WH Geerts, JA Heit, GP Clagett, GF Pineo, CW Colwell, FA Anderson, ...
Chest 119 (1), 132S-175S, 2001
|The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction|
GUSTO Angiographic Investigators
New England Journal of Medicine 329 (22), 1615-1622, 1993
|Executive summary: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines|
GH Guyatt, EA Akl, M Crowther, DD Gutterman, HJ SchuŁnemann
Chest 141 (2 Suppl), 7S, 2012
New England Journal of Medicine 324 (22), 1565-1574, 1991
|Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy|
C Patrono, B Coller, GA FitzGerald, J Hirsh, G Roth
Chest 126 (3), 234S-264S, 2004
|Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer|
PS Wells, DR Anderson, M Rodger, JS Ginsberg, C Kearon, M Gent, ...
Thrombosis and haemostasis 83 (03), 416-420, 2000
|A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis|
M Levine, M Gent, J Hirsh, J Leclerc, D Anderson, J Weitz, J Ginsberg, ...
New England Journal of Medicine 334 (11), 677-681, 1996
|Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events|
JW Eikelboom, J Hirsh, JI Weitz, M Johnston, Q Yi, S Yusuf
Circulation 105 (14), 1650-1655, 2002
|VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical†…|
SM Bates, IA Greer, S Middeldorp, DL Veenstra, AM Prabulos, ...
Chest 141 (2), e691S-e736S, 2012
|A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism|
C Kearon, M Gent, J Hirsh, J Weitz, MJ Kovacs, DR Anderson, AG Turpie, ...
New England Journal of Medicine 340 (12), 901-907, 1999
|Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.|
JI Weitz, M Hudoba, D Massel, J Maraganore, J Hirsh
The Journal of clinical investigation 86 (2), 385-391, 1990
|American Heart Association/American College of Cardiology foundation guide to warfarin therapy|
J Hirsh, V Fuster, J Ansell, JL Halperin
Journal of the American College of Cardiology 41 (9), 1633-1652, 2003